

REMARKS

Applicant points out that after entry of the Amendment and Response to Restriction Requirement filed on December 4, 2007 ("Response"), only claims 25-29 should be pending in this application. Thus, the new restriction requirement seems to be an error. A copy of the Listing of Claims from the Response is attached as an appendix to this paper.


Currently pending claims 25-29 are included in Group II of the most recent restriction requirement and conform to Group II of the restriction requirement set forth in the Office action dated June 7, 2007. Therefore, if required, Applicant elects Group II in response to the restriction requirement.

An election of a single species of DMARD is also required. Although claims 25-29 covers the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for the treatment of rheumatoid arthritis, whether used alone or in combination with other treatments, due to the use of the term "comprises" in the claims, these claims do not specifically include a combination partner. Therefore, Applicant does not believe that the election of a specific DMARD should be required, and believes that this response is complete without such an election. However, the specification indicates that prednisone is the preferred DMARD, and all claims would cover the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide with prednisone.

Entry of this response is requested and an action on the merits is awaited.

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Respectfully submitted,



George R. Dohmann
Attorney for Applicant
Reg. No. 33,593

Date: March 12, 2008